Advertisement

Clinical Rheumatology

, Volume 32, Issue 3, pp 395–398 | Cite as

Limitations of a single-point evaluation of anti-MDA5 antibody, ferritin, and IL-18 in predicting the prognosis of interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis

  • Yoshinao MuroEmail author
  • Kazumitsu Sugiura
  • Masashi Akiyama
Brief Report

Abstract

Autoantibodies against melanoma differentiation-associated gene 5 (MDA5) are important serological markers in dermatomyositis (DM) with rapidly progressive interstitial lung disease (ILD). Recent studies noted that anti-MDA5 antibody (anti-MDA5ab), ferritin, and IL-18 are useful biomarkers for evaluating the responses to treatment and the status of ILD in anti-MDA5ab-positive DM. In this study, we further studied the importance of anti-MDA5ab levels and of ferritin and IL-18 concentrations in our patients. These biomarkers could be sometimes useful for evaluating ILD status and/or predicting the prognosis in patients with anti-MDA5ab-positive DM with several exceptional cases. A single-point evaluation of anti-MDA5ab levels and of ferritin and IL-18 concentrations has limitations in predicting the prognosis of ILD with DM. We consider that the timing of initial therapy and the anti-MDA5ab isotype, in addition to the patient’s age, are also crucial factors for predicting the prognosis.

Keywords

Anti-MDA5 antibody Dermatomyositis Ferritin IL-18 Interstitial lung disease 

Notes

Acknowledgments

This work was supported by grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan (23591618 to YM and 23249058 to MA) and by a grant from the Ministry of Health, Labour and Welfare of Japan (to YM).

Disclosures

None.

References

  1. 1.
    Ye S, Chen XX, Lu XY et al (2007) Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study. Clin Rheumatol 26:1647–1654PubMedCrossRefGoogle Scholar
  2. 2.
    Chen IJ, Jan Wu YJ, Lin CW et al (2009) Interstitial lung disease in polymyositis and dermatomyositis. Clin Rheumatol 28:639–646PubMedCrossRefGoogle Scholar
  3. 3.
    Sato S, Hoshino K, Satoh T et al (2009) RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum 60:2193–2200PubMedCrossRefGoogle Scholar
  4. 4.
    Hoshino K, Muro Y, Sugiura K, Tomita Y, Nakashima R, Mimori T (2010) Anti-MDA5 and anti-TIF1-γ antibodies have clinical significance for patients with dermatomyositis. Rheumatology (Oxford) 49:1726–1733CrossRefGoogle Scholar
  5. 5.
    Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L (2011) The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol 65:25–34PubMedCrossRefGoogle Scholar
  6. 6.
    Gono T, Kawaguchi Y, Satoh T et al (2010) Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford) 49:1713–1719CrossRefGoogle Scholar
  7. 7.
    Gono T, Kawaguchi Y, Hara M et al (2010) Increased ferritin predicts development and severity of acute interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford) 49:1354–1360CrossRefGoogle Scholar
  8. 8.
    Gono T, Kawaguchi Y, Sugiura T et al (2010) Interleukin-18 is a key mediator in dermatomyositis: potential contribution to development of interstitial lung disease. Rheumatology (Oxford) 49:1878–1881CrossRefGoogle Scholar
  9. 9.
    Gono T, Sato S, Kawaguchi Y et al (2012) Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology (Oxford) 51:1563–1570CrossRefGoogle Scholar
  10. 10.
    Muro Y, Sugiura K, Hoshino K, Akiyama M (2012) Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM/interstitial lung disease during disease remission. Rheumatology (Oxford) 51:800–804CrossRefGoogle Scholar
  11. 11.
    Muro Y, Sugiura K, Hoshino K, Akiyama M, Tamakoshi K (2011) Epidemiologic study of clinically amyopathic dermatomyositis and anti-melanoma differentiation-associated gene 5 antibodies in central Japan. Arthritis Res Ther 13:R214PubMedCrossRefGoogle Scholar
  12. 12.
    American Thoracic Society (2000) Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 161(2 Pt 1):646–664Google Scholar
  13. 13.
    Ishikawa A, Muro Y, Sugiura K, Akiyama M (2012) Development of an ELISA for detection of autoantibodies to nuclear matrix protein 2. Rheumatology (Oxford) 51:1181–1187CrossRefGoogle Scholar
  14. 14.
    Kakumanu P, Yamagata H, Sobel ES, Reeves WH, Chan EK, Satoh M (2008) Patients with pulmonary tuberculosis are frequently positive for anti-cyclic citrullinated peptide antibodies, but their sera also react with unmodified arginine-containing peptide. Arthritis Rheum 58:1576–1581PubMedCrossRefGoogle Scholar
  15. 15.
    Nakashima R, Imura Y, Kobayashi S et al (2010) The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxford) 49:433–440CrossRefGoogle Scholar
  16. 16.
    Muro Y (2012) Dermatomyositis. (in Japanese) Jpn J Dermatol 122:3358–3360Google Scholar

Copyright information

© Clinical Rheumatology 2012

Authors and Affiliations

  • Yoshinao Muro
    • 1
    Email author
  • Kazumitsu Sugiura
    • 1
  • Masashi Akiyama
    • 1
  1. 1.Division of Connective Tissue Disease and Autoimmunity, Department of DermatologyNagoya University Graduate School of MedicineNagoyaJapan

Personalised recommendations